About Supriya Lifescience Limited
Data last updated: 30 December 2025
Supriya Lifescience Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 26 March 2008, the company has been in operation for over 18 years.
Registered with ROC Mumbai under CIN L51900MH2008PLC180452. Listed on BSE: 543434 and NSE: SUPRIYA.
Capital: an authorised share capital of ₹35 Cr and a paid-up capital of ₹16.1 Cr. It is led by directors including Dileep Kumar Jain and Smita Satish Wagh.
Last AGM: 24 September 2025. Financial statements filed for year ended 31 March 2025. Office: 207/208 Udyog Bhavan Sonawala Road Goregaon (East), Mumbai, Maharashtra, India – 400063.
As per the financials filed for FY 2025, the company reported a revenue of ₹706.3 Cr, a growth of 22% compared to the previous year.
The company has a workforce of approximately 450 employees as per the latest available data.
The company is associated with 1 brand - Supriya Lifescience. As per MCA filings, the company has open charges of ₹262.41 Cr and satisfied charges of ₹169.96 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website supriyalifescience.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address207/208 Udyog Bhavan Sonawala Road Goregaon (East), Mumbai, Maharashtra, India – 400063
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Supriya Lifescience Limited
Supriya Lifescience Limited has one previous CIN (Corporate Identification Number): U51900MH2008PLC180452. The current CIN is L51900MH2008PLC180452, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L51900MH2008PLC180452 | Current |
| U51900MH2008PLC180452 | Previous |
Associated Brands with Supriya Lifescience Limited
Supriya Lifescience Limited operates one associated brand: Supriya Lifescience. These brands represent Supriya Lifescience Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Active pharmaceutical ingredients and intermediates are manufactured. | supriyalifescience.com |
Business Activity of Supriya Lifescience Limited
Supriya Lifescience Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Supriya Lifescience Limited
Supriya Lifescience Limited is audited by Kakaria & Associates LLP (ICAI peer reviewed, certificate valid till 2027-03-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Kakaria & Associates LLP (ICAI peer reviewed, certificate valid till 2027-03-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Supriya Lifescience Limited
Supriya Lifescience Limited is currently managed by 12 directors, with 20 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Dileep Kumar Jain
Also directs:
Narbada Gems And Jewellery Limited, Lehar Footwears Limited, Supriya Lifescience Limited and 5 more
|
Director | 25 Mar 2021 | 5 Years 3 Months | Current |
|
Smita Satish Wagh
Also directs:
Supriya Lifescience Limited, Supriya Medi-Chem Private Limited
|
Whole-Time Director | 26 Mar 2008 | 18 Years 3 Months | Current |
|
Neelam Yashpal Arora
Also directs:
Supriya Lifescience Limited, Kesar Petroproducts Limited, Shreyas Intermediates Limited and 1 more
|
Director | 25 Mar 2021 | 5 Years 3 Months | Current |
| Sunil Subhash Bhagwat | Additional Director | 24 Jan 2025 | 1 Years 5 Months | Current |
|
Shivani Satish Wagh
Also directs:
Supriya Lifescience Limited
|
Managing Director | 01 Jul 2022 | 4 Years 0 Months | Current |
|
Saloni Satish Wagh
Also directs:
Supriya Lifescience Limited
|
Managing Director | 01 Jul 2022 | 4 Years 0 Months | Current |
Financials of Supriya Lifescience Limited FY 2026 filings available
Supriya Lifescience Limited reported revenue of ₹827.88 Cr (up 18.86% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue from Operations | ₹827.88 Cr | ₹696.49 Cr | ₹570.37 Cr | ₹460.94 Cr | ₹530.05 Cr |
| Other Income | ₹11.49 Cr | ₹9.82 Cr | ₹10.64 Cr | ₹9.49 Cr | ₹7.58 Cr |
| Total Income | ₹839.36 Cr | ₹706.3 Cr | ₹581.01 Cr | ₹470.43 Cr | ₹537.63 Cr |
| Cost of Materials Consumed | ₹265.12 Cr | ₹232.44 Cr | ₹191.43 Cr | ₹187.32 Cr | ₹198.83 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹11.09 Cr | -₹21.26 Cr | ₹30.31 Cr | -₹6.51 Cr | -₹3.03 Cr |
| Employee Benefit Expense | ₹96.68 Cr | ₹80.52 Cr | ₹67.64 Cr | ₹55.58 Cr | ₹49.08 Cr |
| Finance Costs | ₹1.89 Cr | ₹1.69 Cr | ₹2.11 Cr | ₹3.08 Cr | ₹4.2 Cr |
| Depreciation & Amortisation | ₹28.41 Cr | ₹20.44 Cr | ₹15.81 Cr | ₹11.82 Cr | ₹10.12 Cr |
| Other Expenses | ₹183.12 Cr | ₹143.99 Cr | ₹108.02 Cr | ₹95.65 Cr | ₹71.18 Cr |
| Total Expenses | ₹564.13 Cr | ₹457.82 Cr | ₹415.32 Cr | ₹346.94 Cr | ₹330.38 Cr |
| Profit Before Exceptional Items & Tax | ₹275.24 Cr | ₹248.48 Cr | ₹165.69 Cr | ₹123.49 Cr | ₹207.25 Cr |
| Exceptional Items | -₹45.8 Lakh | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹274.78 Cr | ₹248.48 Cr | ₹165.69 Cr | ₹123.49 Cr | ₹207.25 Cr |
| Total Tax Expense | ₹65.66 Cr | ₹60.52 Cr | ₹46.58 Cr | ₹33.63 Cr | ₹55.44 Cr |
| Net Profit | ₹209.12 Cr | ₹187.96 Cr | ₹119.11 Cr | ₹89.86 Cr | ₹151.81 Cr |
| Other Comprehensive Income | -₹9.9 Lakh | -₹12.5 Lakh | ₹1.62 Cr | -₹1.26 Cr | -₹31.5 Lakh |
| Total Comprehensive Income | ₹209.02 Cr | ₹187.83 Cr | ₹120.74 Cr | ₹88.6 Cr | ₹151.5 Cr |
| EBITDA (computed) | ₹305.54 Cr | ₹270.61 Cr | ₹183.61 Cr | ₹138.39 Cr | ₹221.56 Cr |
| Basic EPS | ₹25.98 | ₹23.35 | ₹14.80 | ₹11.16 | ₹18.86 |
| Diluted EPS | ₹25.98 | ₹23.35 | ₹14.80 | ₹11.16 | ₹18.86 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹1,357.11 Cr | ₹1,112.31 Cr | ₹921.24 Cr | ₹820.28 Cr |
| Non-current Assets | ₹824.8 Cr | ₹675.28 Cr | ₹523.43 Cr | ₹355.39 Cr |
| Current Assets | ₹532.3 Cr | ₹437.04 Cr | ₹397.8 Cr | ₹464.89 Cr |
| Property, Plant & Equipment | ₹683.32 Cr | ₹451.48 Cr | ₹303.7 Cr | ₹255.12 Cr |
| Inventories | ₹159.6 Cr | ₹118.35 Cr | ₹85.25 Cr | ₹115.77 Cr |
| Trade Receivables | ₹219.45 Cr | ₹134.36 Cr | ₹111.68 Cr | ₹84.66 Cr |
| Cash & Equivalents | ₹37.55 Cr | ₹76.06 Cr | ₹68.35 Cr | ₹85.25 Cr |
| Equity (Net Worth) | ₹1,197.73 Cr | ₹996.76 Cr | ₹815.37 Cr | ₹699.46 Cr |
| Equity Share Capital | ₹16.1 Cr | ₹16.1 Cr | ₹16.1 Cr | ₹16.1 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 | ₹16.63 Cr |
| Total Debt (computed) | ₹0 | ₹0 | ₹0 | ₹16.63 Cr |
| Current Liabilities | ₹121.04 Cr | ₹82.16 Cr | ₹76.89 Cr | ₹95.78 Cr |
| Total Liabilities | ₹159.37 Cr | ₹115.55 Cr | ₹105.87 Cr | ₹120.82 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹185.77 Cr | ₹164.68 Cr | ₹113.31 Cr | ₹66.19 Cr | ₹48.8 Cr |
| Investing Cash Flow | -₹176.17 Cr | -₹152.25 Cr | -₹173.58 Cr | -₹133.1 Cr | -₹59.82 Cr |
| Financing Cash Flow | -₹9.88 Cr | -₹8.23 Cr | -₹22.36 Cr | -₹3.37 Cr | ₹149.65 Cr |
| Capital Expenditure | ₹152.24 Cr | ₹162.38 Cr | ₹145.66 Cr | ₹108.4 Cr | ₹59.9 Cr |
| Free Cash Flow (computed) | ₹33.53 Cr | ₹2.3 Cr | -₹32.35 Cr | -₹42.21 Cr | -₹11.1 Cr |
| Dividends Paid | ₹8.05 Cr | ₹6.44 Cr | ₹4.83 Cr | ₹4.83 Cr | ₹4.39 Cr |
| Net Change in Cash | -₹28.7 Lakh | ₹4.2 Cr | -₹82.63 Cr | -₹70.28 Cr | ₹138.63 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹276.53 Cr | ₹206.44 Cr | ₹199.83 Cr | ₹145.07 Cr | ₹184.11 Cr | ₹185.65 Cr | ₹166.1 Cr | ₹160.63 Cr | ₹158.18 Cr | ₹140.07 Cr | ₹140.1 Cr | ₹132.02 Cr |
| Other Income | ₹3.48 Cr | ₹2.61 Cr | ₹2.73 Cr | ₹2.67 Cr | ₹2.98 Cr | ₹2.1 Cr | ₹2.52 Cr | ₹2.22 Cr | ₹2.19 Cr | ₹3.07 Cr | ₹2.47 Cr | ₹2.92 Cr |
| Total Income | ₹280.01 Cr | ₹209.05 Cr | ₹202.56 Cr | ₹147.75 Cr | ₹187.08 Cr | ₹187.75 Cr | ₹168.62 Cr | ₹162.85 Cr | ₹160.37 Cr | ₹143.14 Cr | ₹142.56 Cr | ₹134.94 Cr |
| Cost of Materials Consumed | ₹83.36 Cr | ₹77.3 Cr | ₹60.68 Cr | ₹43.78 Cr | ₹101.53 Cr | ₹13.6 Cr | ₹61.58 Cr | ₹55.73 Cr | ₹48.36 Cr | ₹44.84 Cr | ₹50.7 Cr | ₹47.53 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹21.97 Cr | -₹16.1 Cr | -₹4.95 Cr | -₹12 Cr | -₹46.71 Cr | ₹48.18 Cr | -₹15.61 Cr | -₹7.13 Cr | ₹9.91 Cr | ₹9.78 Cr | ₹10.94 Cr | -₹30.8 Lakh |
| Employee Benefit Expense | ₹24.82 Cr | ₹24.69 Cr | ₹24.48 Cr | ₹22.69 Cr | ₹20.98 Cr | ₹19.77 Cr | ₹19.69 Cr | ₹20.08 Cr | ₹17.14 Cr | ₹17.56 Cr | ₹17.5 Cr | ₹15.43 Cr |
| Finance Costs | ₹46.8 Lakh | ₹49.4 Lakh | ₹41.5 Lakh | ₹51.2 Lakh | ₹41.7 Lakh | ₹50.65 Lakh | ₹42.7 Lakh | ₹33.5 Lakh | ₹60.1 Lakh | ₹49.4 Lakh | ₹46 Lakh | ₹81.6 Lakh |
| Depreciation & Amortisation | ₹8.5 Cr | ₹6.82 Cr | ₹6.64 Cr | ₹6.45 Cr | ₹6.08 Cr | ₹4.96 Cr | ₹4.74 Cr | ₹4.66 Cr | ₹3.91 Cr | ₹3.96 Cr | ₹3.98 Cr | ₹3.96 Cr |
| Other Expenses | ₹48.77 Cr | ₹48.46 Cr | ₹46.98 Cr | ₹38.91 Cr | ₹40.72 Cr | ₹38.14 Cr | ₹35.73 Cr | ₹29.4 Cr | ₹27.27 Cr | ₹26.4 Cr | ₹29.2 Cr | ₹24.88 Cr |
| Total Expenses | ₹187.88 Cr | ₹141.67 Cr | ₹134.24 Cr | ₹100.34 Cr | ₹123.02 Cr | ₹125.17 Cr | ₹106.56 Cr | ₹103.08 Cr | ₹107.19 Cr | ₹103.04 Cr | ₹112.78 Cr | ₹92.3 Cr |
| Profit Before Exceptional Items & Tax | ₹92.13 Cr | ₹67.38 Cr | ₹68.32 Cr | ₹47.41 Cr | ₹64.06 Cr | ₹62.58 Cr | ₹62.06 Cr | ₹59.78 Cr | ₹53.17 Cr | ₹40.1 Cr | ₹29.78 Cr | ₹42.64 Cr |
| Exceptional Items | ₹0 | -₹45.8 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹92.13 Cr | ₹66.92 Cr | ₹68.32 Cr | ₹47.41 Cr | ₹64.06 Cr | ₹62.58 Cr | ₹62.06 Cr | ₹59.78 Cr | ₹53.17 Cr | ₹40.1 Cr | ₹29.78 Cr | ₹42.64 Cr |
| Total Tax Expense | ₹17.9 Cr | ₹17.25 Cr | ₹17.89 Cr | ₹12.62 Cr | ₹13.68 Cr | ₹15.8 Cr | ₹15.92 Cr | ₹15.13 Cr | ₹16.24 Cr | ₹10.31 Cr | ₹5.89 Cr | ₹14.13 Cr |
| Net Profit | ₹74.23 Cr | ₹49.68 Cr | ₹50.43 Cr | ₹34.79 Cr | ₹50.38 Cr | ₹46.78 Cr | ₹46.15 Cr | ₹44.64 Cr | ₹36.93 Cr | ₹29.79 Cr | ₹23.88 Cr | ₹28.51 Cr |
| Other Comprehensive Income | ₹4.1 Lakh | ₹4 Lakh | ₹3.4 Lakh | -₹21.5 Lakh | ₹8.7 Lakh | ₹6.04 Lakh | -₹21.7 Lakh | -₹5.5 Lakh | ₹5.6 Lakh | ₹27 Lakh | -₹13.8 Lakh | -₹1.46 Cr |
| Total Comprehensive Income | ₹74.27 Cr | ₹49.72 Cr | ₹50.46 Cr | ₹34.58 Cr | ₹50.47 Cr | ₹46.84 Cr | ₹45.93 Cr | ₹44.59 Cr | ₹36.99 Cr | ₹30.06 Cr | ₹23.75 Cr | ₹27.06 Cr |
| EBITDA (computed) | ₹101.1 Cr | ₹74.69 Cr | ₹75.37 Cr | ₹54.38 Cr | ₹70.56 Cr | ₹68.05 Cr | ₹67.24 Cr | ₹64.77 Cr | ₹57.69 Cr | ₹44.55 Cr | ₹34.22 Cr | ₹47.41 Cr |
| Basic EPS | ₹9.22 | ₹6.17 | ₹6.27 | ₹4.32 | ₹6.29 | ₹5.82 | ₹5.71 | ₹5.54 | ₹4.59 | ₹3.70 | ₹2.97 | ₹3.54 |
| Diluted EPS | ₹9.22 | ₹6.17 | ₹6.27 | ₹4.32 | ₹6.29 | ₹5.82 | ₹5.71 | ₹5.54 | ₹4.59 | ₹3.70 | ₹2.97 | ₹3.54 |
Shareholding Pattern of Supriya Lifescience Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 68.30%, foreign institutional investors hold 5.16%, domestic institutional investors hold 5.70%, retail and other public shareholders hold 20.84% of Supriya Lifescience Limited. The company had 81,161 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% |
| Public | 31.70% | 31.70% | 31.70% | 31.70% | 31.70% | 31.70% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | |
|---|---|---|---|---|---|
| Promoters | 68.30% | 68.30% | 68.30% | 68.28% | 68.24% |
| Public | 31.70% | 31.70% | 31.70% | 31.72% | 31.76% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | +0.02 | +0.04 | - |
Board & Governance of Supriya Lifescience Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Supriya Lifescience Limited has 12 directors - 7 independent and 5 executive. The board is chaired by Satish Waman Wagh.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Satish Waman Wagh | Executive Director · Chairperson | 2008-03-26 | 1 |
| Smita Satish Wagh | Executive Director | 2008-03-26 | 1 |
| Saloni Satish Wagh | Executive Director · MD | 2019-07-01 | 1 |
| Shivani Satish Wagh | Executive Director · MD | 2019-07-01 | 1 |
| Balasaheb Gulabrao Sawant | Executive Director | 2023-05-26 | 1 |
| Dileep Kumar Jain | Non-Executive - Independent Director | 2021-03-25 | 4 |
| Dinesh Navnitlal Modi | Non-Executive - Independent Director | 2021-03-25 | 1 |
| Neelam Yashpal Arora | Non-Executive - Independent Director | 2021-03-25 | 3 |
| Ganapati Dadasaheb Yadav | Non-Executive - Independent Director | 2025-01-24 | 5 |
| Sunil Subhash Bhagwat | Non-Executive - Independent Director | 2025-01-24 | 1 |
| Manish Ishwarlal Panchal | Non-Executive - Independent Director | 2026-02-09 | 2 |
| Kothandaraman Hari | Non-Executive - Independent Director | 2026-02-09 | 2 |
| Committee | Members |
|---|---|
| Audit Committee | Dinesh Navnitlal Modi (Chairperson), Ganapati Dadasaheb Yadav, Satish Waman Wagh, Kothandaraman Hari (Chairperson), Manish Ishwarlal Panchal |
| Nomination and remuneration committee | Dinesh Navnitlal Modi (Chairperson), Sunil Subhash Bhagwat, Dileep Kumar Jain, Manish Ishwarlal Panchal, Kothandaraman Hari (Chairperson) |
| Stakeholders Relationship Committee | Dileep Kumar Jain (Chairperson), Satish Waman Wagh, Saloni Satish Wagh, Manish Ishwarlal Panchal (Chairperson) |
| Risk Management Committee | Satish Waman Wagh (Chairperson), Saloni Satish Wagh, Ganapati Dadasaheb Yadav |
| Corporate Social Responsibility Committee | Satish Waman Wagh (Chairperson), Saloni Satish Wagh, Sunil Subhash Bhagwat |
Charges & Borrowings of Supriya Lifescience Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Jun 2025 | Idbi Trusteeship Services Limited | ₹114 Cr | Open |
| 03 May 2024 | Axis Bank Limited | ₹44 Cr | Open |
| 17 Apr 2024 | Others | ₹30 Cr | Open |
| 05 Jul 2012 | The Saraswat Cooperative Bank Ltd | ₹2 Cr | Open |
| 27 Jun 2009 | The Saraswat Cooperative Bank Ltd | ₹10.91 Cr | Open |
Total charge records: 45 View all charges
Employees and EPFO Compliance at Supriya Lifescience Limited
Supriya Lifescience Limited has a workforce of 450 employees as of Apr 04, 2025.
Employee Count & EPFO Data of Supriya Lifescience Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Supriya Lifescience Limited
GSTIN & GST Filing Data of Supriya Lifescience Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Supriya Lifescience Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Supriya Lifescience Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Supriya Lifescience Limited
MSME Payment Delays by Supriya Lifescience Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Supriya Lifescience Limited
Subsidiaries & Group Companies of Supriya Lifescience Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Supriya Lifescience Limited with ownership details.
MCA Filings & Documents of Supriya Lifescience Limited
MCA Filings & Documents of Supriya Lifescience Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Supriya Lifescience Limited
Recent News on Supriya Lifescience Limited
Frequently Asked Questions about Supriya Lifescience Limited
Supriya Lifescience Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 26 March 2008 (18+ years old) and is registered under CIN L51900MH2008PLC180452. Listed on BSE: 543434 and NSE: SUPRIYA. The company has 450 employees.
Supriya Lifescience Limited reported revenue of ₹706.3 Cr for FY 2025 (up 22.00% YoY).
The current directors of Supriya Lifescience Limited are:
The primary industry of Supriya Lifescience Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Supriya Lifescience Limited is listed on both BSE (code: 543434) and NSE (symbol: SUPRIYA).
Supriya Lifescience Limited can be reached at the registered office: 207208 Udyog Bhavan Sonawala Road Goregaon East, Mumbai, Maharashtra, India – 400063, or through the website supriyalifescience.com.